Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience

Basit Öğe Kaydı
dc.contributor.authorCetin, Bulent
dc.contributor.authorBenekli, Mustafa
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorKoral, Lokman
dc.contributor.authorUlas, Arife
dc.contributor.authorDane, Faysal
dc.contributor.authorTurker, Ibrahim
dc.date.accessioned2024-04-24T17:14:28Z
dc.date.available2024-04-24T17:14:28Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: We investigated the clinical outcome of patients with brain metastases (BMs) from human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) treated with lapatinib and capecitabine (LC). Patients and Methods: A total of 203 patients with HER2+ MBC, who had progressed after trastuzumab-containing chemotherapy, were retrospectively evaluated in 11 centers between September 2009 and May 2011. 85 patients who had developed BMs before the initiation of treatment with LC were included. All patients had received prior cranial radiotherapy. All patients were treated with the combination of lapatinib (1,250 mg/day continuously) and capecitabine (2,000 mg/m(2) on days 1-14 of a 21-day cycle). Results: The median follow-up was 10.5 months (range 1-38 months). An overall response rate of 27.1% was achieved, including complete response in 2 (2.4%) and partial response in 21 (24.7%) patients. Median progression-free survival was 7 months (95% confidence interval (CI) 5-9), with a median overall survival of 13 months (95% Cl 9-17). The most common side effects were hand-foot syndrome (58.8%), nausea (55.3%), fatigue (48.9%), anorexia (45.9%), rash (36.5%), and diarrhea (35.4%). Grade 3-4 toxicities were hand-foot syndrome (9.4%), diarrhea (8.3%), fatigue (5.9%), and rash (4.7%). There were no symptomatic cardiac events. Conclusion: LC combination therapy was effective and well-tolerated in patients with HER2+ MBC with BMs, who had progressive disease after trastuzumab-containing therapy.en_US
dc.identifier.doi10.1159/000345040
dc.identifier.endpage745en_US
dc.identifier.issn0378-584X
dc.identifier.issn1423-0240
dc.identifier.issue12en_US
dc.identifier.pmid23207619
dc.identifier.scopus2-s2.0-84871057384
dc.identifier.scopusqualityQ4
dc.identifier.startpage740en_US
dc.identifier.urihttps://doi.org/10.1159/000345040
dc.identifier.urihttps://hdl.handle.net/11468/17972
dc.identifier.volume35en_US
dc.identifier.wosWOS:000312469400003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOnkologie
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHer2en_US
dc.subjectMetastatic Breast Canceren_US
dc.subjectLapatiniben_US
dc.subjectBrain Metastasesen_US
dc.titleLapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experienceen_US
dc.titleLapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu